# Tissue preparation and assay suitability

Source: https://onco.cc/terms/tissue-preparation-assay-fit/  
OnCo record `tissue-preparation-assay-fit` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Fixed, frozen and living tissue preserve different properties. A preparation that works for one test may not support another.

## Summary

Paired-specimen studies found that fixation and extraction changed nucleic-acid measurements relative to fresh-frozen material. Viable organoid studies examine a different property: whether living cells can establish the studied culture. Preserved morphology, recoverable DNA or RNA, and viable cell behavior are therefore different specimen requirements. No preparation is universally best; the intended measurement and evidence for that particular workflow determine suitability.

## Fields

- Kind: Term
- Last checked: 2026-11-10
- Also known as: FFPE versus fresh-frozen versus viable tissue; specimen fitness for purpose

## Notes

- Formalin-fixed paraffin-embedded material preserves architecture and supports assays validated for its altered molecules, but cannot restore the original living cells. Snap-freezing preserves material for molecular analysis; the NCI protocol excludes viability, sorting and culture endpoints. A viable-cell vial requires verified recovery, identity and function for its intended assay. No preparation label measures tumour content.
- Masuda experimentally demonstrated chemical modifications of fixed RNA and effects on amplification. Recovering RNA or DNA does not undo fixation or establish a viable cell. Fixed material can still support suitable molecular assays. Fresh and frozen labels describe handling history rather than a verified fraction of living malignant cells.
- Fictional archive: a fixed block, a snap-frozen piece and a vial labelled viable are offered for a cell-growth perturbation. None of these labels alone establishes suitability. The fixed block cannot supply its original living cells; the frozen piece may not be preserved for viable recovery; the viable vial needs recovery, relevant cell identity and model function checked. A successful culture can select a changed cell mixture rather than reproduce the archive.
- Preparation can irreversibly close options. If fixed molecular assays and living-cell experiments are both contemplated, their inputs and separate aliquots need planning before processing, while protecting diagnostic requirements. There is no universally best preparation; dividing finite tissue also has a cost.
- Assess suitability by documenting preservation, checking which cells are represented and applying quality checks for the intended assay or living-cell workflow. Sections, tissue pieces and cell aliquots are finite, and destructive quality checks also use material. Report analyte-appropriate yield and quality, or viable-cell recovery and function when those are required. The receiving method defines acceptance: a preservation label alone guarantees no pass. Delayed stabilisation, incompatible fixative, degraded analyte, poor thaw recovery and missing target cells can defeat the question. Validation on fixed tissue does not automatically transfer to frozen or cultured material, and input suitability alone proves neither clinical accuracy, tumour-wide representation nor patient drug response.

## Sources

- Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue.: https://doi.org/10.1371/journal.pone.0098187
- The Biospecimen Preanalytical Variables Program: A Multiassay Comparison of Effects of Delay to Fixation and Fixation Duration on Nucleic Acid Quality.: https://doi.org/10.5858/arpa.2018-0172-oa
- A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.: https://doi.org/10.1016/j.cell.2017.11.010
- NCI Biospecimen Evidence-Based Practices: snap-freezing of post-surgical tissue: https://dctd.cancer.gov/data-tools-biospecimens/snap-freeze-bebp.pdf
- Biospecimen & Biorepository Basics - NCI: https://dctd.cancer.gov/data-tools-biospecimens/biospecimens-biobanks/basics
- Surgical Pathology Reports - NCI: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/pathology-reports-fact-sheet
- Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples.: https://pubmed.ncbi.nlm.nih.gov/10536153/
- Organoid Modeling of the Tumor Immune Microenvironment.: https://pubmed.ncbi.nlm.nih.gov/30550791/

## Connected records

- technologies: [Imaging mass cytometry](https://onco.cc/technologies/imaging-mass-cytometry/), [Patient-derived organoids](https://onco.cc/technologies/organoids/), [Pre-analytics: blood-collection tubes and tissue fixation](https://onco.cc/technologies/preanalytics-sample-stabilisation/), [Proteomics & phosphoproteomics](https://onco.cc/technologies/proteomics/)
- terms: [Finite tissue and specimen allocation](https://onco.cc/terms/finite-tissue-budget/), [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Peripheral blood mononuclear cell specimens](https://onco.cc/terms/pbmc-specimens/), [Reverse-phase protein array (RPPA)](https://onco.cc/terms/rppa/), [RNA integrity and assay suitability](https://onco.cc/terms/rna-integrity/), [Specimen provenance and derivative tracking](https://onco.cc/terms/specimen-provenance/), [Targeted proteomics and quantification limits](https://onco.cc/terms/targeted-proteomics-quantification/)

---
JSON: https://onco.cc/api/v1/entities/tissue-preparation-assay-fit.json